US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Alumis Inc.

29.39

+1.314.67%

Post-market: 28.81-0.5800-1.97%19:55 EST

Volume:1.09M

Turnover:32.26M

Market Cap:3.59B

PE:-7.62

High:30.03

Open:28.87

Low:28.64

Close:28.08

52wk High:30.60

52wk Low:2.76

Shares:122.00M

Float Shares:77.49M

Volume Ratio:0.71

T/O Rate:1.41%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.8545

EPS(LYR):-10.3816

ROE:-66.88%

ROA:-61.46%

PB:9.32

PE(LYR):-2.83

Loading ...

Overview Company News Filings

Alumis (ALMS.US) Soars Over 154% at Open on Positive Phase 3 Psoriasis Drug Trial Results

Stock Track | Alumis Inc. Soars 167.51% in Pre-Market on Positive Phase 3 Psoriasis Drug Results

Alumis Shares Jump 155% to $21 After Co's Skin Disease Drug Meets Main Goal of Two Late Stage Trials

THOMSON REUTERS

BUZZ-U.S. STOCKS ON THE MOVE-Alkermes, Ball Corp, NovaBridge

Alumis Exec Says Co Believes Envudeucitinib Is "Very Competitive" With Takeda's Zasocitinib - Conf Call

THOMSON REUTERS

Alumis Shares Surge 90% as Its Skin Disease Drug Meets Main Goal in Late-Stage Trials

Stock Track | Alumis Inc. Soars 94.46% in Pre-Market After Positive Phase 3 Psoriasis Drug Results

Alumis Shares Extend Premarket Gains, Last up 104% at $17

THOMSON REUTERS

Alumis Shares Jump 17.2% to $9.74 Premarket After Co's Skin Disease Drug Meets Main Goal of Two Late Stage Trials

THOMSON REUTERS

Alumis Inc - Envudeucitinib Shows Favorable Safety and Tolerability Profile Consistent With the Phase 2 Program

THOMSON REUTERS

Alumis Inc - Phase 3 Trials Meet All Endpoints With High Statistical Significance

THOMSON REUTERS

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

THOMSON REUTERS

Alumis Inc - to Submit New Drug Application to FDA in H2 2026

THOMSON REUTERS

Alumis Inc - Topline Data From Lumus Phase 2B Trial of Envudeucitinib in Sle Expected to Be Announced in Q3 2026

THOMSON REUTERS

Alumis Reports Positive Phase 3 Results for Envudeucitinib in Plaque Psoriasis

Stocks to Watch: Cyclerion, Vistra, Zeta Global, Alumis

Alumis Shares Rise on Plans to Share Trial Data for Plaque Psoriasis Treatment

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

BRIEF-Alumis Inc - Co & Its Unit Issues Notice Of Material Breach & Notification Of Claim For Indemnification To Climb Bio - SEC Filing

Alumis Inc - Co & Its Unit Issues Notice of Material Breach & Notification of Claim for Indemnification to Climb Bio - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALMS/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALMS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":29.39,"timestamp":1772053200000,"preClose":28.08,"halted":0,"volume":1091602,"hourTrading":{"tag":"盘后","latestPrice":28.81,"preClose":29.39,"latestTime":"19:55 EST","volume":33724,"amount":990704.0743,"timestamp":1772067340691,"change":-0.58,"changeRate":-0.019735,"amplitude":0.019735},"delay":0,"changeRate":0.046652421652421734,"floatShares":77486300,"shares":122000000,"eps":-3.8545,"marketStatus":"Closed","change":1.31,"latestTime":"02-25 16:00:00 EST","open":28.865,"high":30.03,"low":28.635,"amount":32256954.809812,"amplitude":0.049679,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.8545,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772096400000},"marketStatusCode":5,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":28.08,"preHourTrading":{"tag":"盘前","latestPrice":28.92,"preClose":28.08,"latestTime":"09:29 EST","volume":122,"amount":3505.96951,"timestamp":1772029799961,"change":0.84,"changeRate":0.029915,"amplitude":0.057518},"postHourTrading":{"tag":"盘后","latestPrice":28.81,"preClose":29.39,"latestTime":"19:55 EST","volume":33724,"amount":990704.0743,"timestamp":1772067340691,"change":-0.58,"changeRate":-0.019735,"amplitude":0.019735},"volumeRatio":0.710553,"impliedVol":0.9611,"impliedVolPercentile":0.2579},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","floatShares":77486300,"roa":"-61.46%","roe":"-66.88%","lyrEps":-10.381567,"volumeRatio":0.710553,"shares":122000000,"dividePrice":0,"high":30.03,"amplitude":0.049679,"preClose":28.08,"low":28.635,"week52Low":2.7601,"pbRate":"9.32","psRate":"162.09","week52High":30.6,"institutionHeld":0,"latestPrice":29.39,"eps":-3.8545,"divideRate":0,"volume":1091602,"delay":0,"ttmEps":-3.8545,"open":28.865,"prevYearClose":9.76,"prevWeekClose":27.97,"prevMonthClose":24.51,"prevQuarterClose":9.76,"fiveDayClose":27.51,"twentyDayClose":26,"sixtyDayClose":7.64},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALMS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"ALMS","fiscalQuarterEnding":"2025/09","expectedEps":-0.92,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-1.06},{"market":"US","date":"2025-08-13","symbol":"ALMS","fiscalQuarterEnding":"2025/06","expectedEps":-1.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-1.17},{"market":"US","date":"2025-05-14","symbol":"ALMS","fiscalQuarterEnding":"2025/03","expectedEps":-1.47,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-1.82},{"market":"US","date":"2025-03-19","symbol":"ALMS","fiscalQuarterEnding":"2024/12","expectedEps":-1.39,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742356800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-13","symbol":"ALMS","fiscalQuarterEnding":"2024/09","expectedEps":-1.64,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-1.73}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALMS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALMS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":8,"updateTime":1753678800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALMS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALMS","date":"2026-02-24","current":-7.746789,"percent":0.007212,"low":-14.850306,"twenty":-3.708544,"median":-2.081121,"eighty":-0.973379,"high":-0.443678,"avg":-3.001685,"sd":3.093859,"marketCap":3446756068},"quantilePoints":[{"date":"2024-06-28","current":-4.084559,"twenty":-4.913756,"median":-4.913756,"eighty":-4.416238,"marketCap":689534895},{"date":"2024-07-05","current":-3.516406,"twenty":-4.747917,"median":-3.851156,"eighty":-3.59564,"marketCap":593622147},{"date":"2024-07-12","current":-3.405847,"twenty":-4.063676,"median":-3.825051,"eighty":-3.58397,"marketCap":574958044},{"date":"2024-07-19","current":-4.023985,"twenty":-4.026561,"median":-3.851156,"eighty":-3.52869,"marketCap":679309112},{"date":"2024-07-26","current":-4.023985,"twenty":-4.117224,"median":-3.947896,"eighty":-3.58397,"marketCap":679309112},{"date":"2024-08-02","current":-4.178507,"twenty":-4.123137,"median":-3.980142,"eighty":-3.620209,"marketCap":705394582},{"date":"2024-08-09","current":-3.850149,"twenty":-4.108328,"median":-3.938677,"eighty":-3.693301,"marketCap":649962958},{"date":"2024-08-16","current":-3.683794,"twenty":-4.085032,"median":-3.914533,"eighty":-3.659692,"marketCap":696362265},{"date":"2024-08-23","current":-3.672282,"twenty":-4.078883,"median":-3.855481,"eighty":-3.667968,"marketCap":694186133},{"date":"2024-08-30","current":-3.655014,"twenty":-4.050383,"median":-3.84693,"eighty":-3.659692,"marketCap":690921935},{"date":"2024-09-06","current":-3.442045,"twenty":-4.027205,"median":-3.798947,"eighty":-3.608967,"marketCap":650663491},{"date":"2024-09-13","current":-3.33556,"twenty":-4.023985,"median":-3.741353,"eighty":-3.511116,"marketCap":630534270},{"date":"2024-09-20","current":-3.301025,"twenty":-4.023985,"median":-3.709695,"eighty":-3.405847,"marketCap":624005873},{"date":"2024-09-27","current":-3.211808,"twenty":-3.980142,"median":-3.685233,"eighty":-3.395997,"marketCap":607140850},{"date":"2024-10-04","current":-2.803137,"twenty":-3.959602,"median":-3.672282,"eighty":-3.303903,"marketCap":529888161},{"date":"2024-10-11","current":-2.978693,"twenty":-3.946725,"median":-3.656453,"eighty":-3.263611,"marketCap":563074175},{"date":"2024-10-18","current":-3.462191,"twenty":-3.930629,"median":-3.608967,"eighty":-3.220442,"marketCap":654471723},{"date":"2024-10-25","current":-3.424777,"twenty":-3.915649,"median":-3.608753,"eighty":-3.22332,"marketCap":647399293},{"date":"2024-11-01","current":-3.254977,"twenty":-3.914533,"median":-3.516406,"eighty":-3.231953,"marketCap":615301345},{"date":"2024-11-08","current":-3.459313,"twenty":-3.86344,"median":-3.50536,"eighty":-3.240587,"marketCap":653927690},{"date":"2024-11-15","current":-2.016571,"twenty":-3.859807,"median":-3.465068,"eighty":-3.22332,"marketCap":481504843},{"date":"2024-11-22","current":-2.155567,"twenty":-3.851156,"median":-3.454996,"eighty":-3.18015,"marketCap":514693313},{"date":"2024-11-29","current":-2.109995,"twenty":-3.85035,"median":-3.444923,"eighty":-3.067334,"marketCap":503811848},{"date":"2024-12-06","current":-2.050751,"twenty":-3.847574,"median":-3.439167,"eighty":-2.978693,"marketCap":489665943},{"date":"2024-12-13","current":-1.911755,"twenty":-3.823752,"median":-3.419021,"eighty":-2.94646,"marketCap":456477473},{"date":"2024-12-20","current":-2.009736,"twenty":-3.802749,"median":-3.405847,"eighty":-2.329653,"marketCap":479872624},{"date":"2024-12-27","current":-1.836561,"twenty":-3.764391,"median":-3.395997,"eighty":-2.153744,"marketCap":438523055},{"date":"2025-01-03","current":-1.925427,"twenty":-3.741353,"median":-3.367218,"eighty":-2.142807,"marketCap":459741913},{"date":"2025-01-10","current":-1.595028,"twenty":-3.741353,"median":-3.312536,"eighty":-2.023407,"marketCap":380851289},{"date":"2025-01-17","current":-1.745417,"twenty":-3.740777,"median":-3.298147,"eighty":-1.989684,"marketCap":416760124},{"date":"2025-01-24","current":-1.522113,"twenty":-3.738475,"median":-3.27944,"eighty":-1.964163,"marketCap":363440944},{"date":"2025-01-31","current":-1.704402,"twenty":-3.735597,"median":-3.263611,"eighty":-1.93682,"marketCap":406966805},{"date":"2025-02-07","current":-1.291973,"twenty":-3.709695,"median":-3.247782,"eighty":-1.911755,"marketCap":308489544},{"date":"2025-02-14","current":-1.187157,"twenty":-3.703939,"median":-3.22332,"eighty":-1.873019,"marketCap":283462173},{"date":"2025-02-21","current":-1.178042,"twenty":-3.690125,"median":-3.211808,"eighty":-1.829725,"marketCap":281285880},{"date":"2025-02-28","current":-1.059555,"twenty":-3.68437,"median":-3.162882,"eighty":-1.759544,"marketCap":252994070},{"date":"2025-03-07","current":-1.111963,"twenty":-3.676887,"median":-3.070787,"eighty":-1.711693,"marketCap":265507755},{"date":"2025-03-14","current":-1.041326,"twenty":-3.672858,"median":-3.006033,"eighty":-1.678881,"marketCap":248641484},{"date":"2025-03-21","current":-0.693421,"twenty":-3.667968,"median":-2.978693,"eighty":-1.565406,"marketCap":204027476},{"date":"2025-03-28","current":-1.042906,"twenty":-3.659692,"median":-2.965742,"eighty":-1.505251,"marketCap":306857324},{"date":"2025-04-04","current":-1.85837,"twenty":-3.65559,"median":-2.803137,"eighty":-1.500694,"marketCap":546793636},{"date":"2025-04-11","current":-1.198232,"twenty":-3.63199,"median":-2.286587,"eighty":-1.463027,"marketCap":352559478},{"date":"2025-04-17","current":-0.924562,"twenty":-3.622781,"median":-2.176074,"eighty":-1.280365,"marketCap":272036635},{"date":"2025-04-25","current":-0.791425,"twenty":-3.613572,"median":-2.146452,"eighty":-1.183511,"marketCap":232863359},{"date":"2025-05-02","current":-0.848748,"twenty":-3.60871,"median":-2.125945,"eighty":-1.162092,"marketCap":249729630},{"date":"2025-05-09","current":-0.930109,"twenty":-3.590112,"median":-2.016571,"eighty":-1.140673,"marketCap":273668854},{"date":"2025-05-16","current":-0.890525,"twenty":-3.561975,"median":-1.997203,"eighty":-1.105127,"marketCap":305759157},{"date":"2025-05-23","current":-0.766929,"twenty":-3.530406,"median":-1.968721,"eighty":-1.070948,"marketCap":263322832},{"date":"2025-05-30","current":-0.619565,"twenty":-3.51429,"median":-1.964163,"eighty":-1.045883,"marketCap":212725677},{"date":"2025-06-06","current":-0.530829,"twenty":-3.506511,"median":-1.95277,"eighty":-1.037224,"marketCap":182258572},{"date":"2025-06-13","current":-0.503891,"twenty":-3.48667,"median":-1.925427,"eighty":-0.984896,"marketCap":173009629},{"date":"2025-06-20","current":-0.476954,"twenty":-3.466829,"median":-1.916313,"eighty":-0.943233,"marketCap":163760687},{"date":"2025-06-27","current":-0.522906,"twenty":-3.464493,"median":-1.909477,"eighty":-0.920124,"marketCap":179538295},{"date":"2025-07-03","current":-0.538752,"twenty":-3.462191,"median":-1.878715,"eighty":-0.88573,"marketCap":184978849},{"date":"2025-07-11","current":-0.564105,"twenty":-3.459313,"median":-1.85837,"eighty":-0.848748,"marketCap":193683736},{"date":"2025-07-18","current":-0.556182,"twenty":-3.450679,"median":-1.833144,"eighty":-0.808067,"marketCap":190963459},{"date":"2025-07-25","current":-0.611642,"twenty":-3.444923,"median":-1.819538,"eighty":-0.791425,"marketCap":210005399},{"date":"2025-08-01","current":-0.65601,"twenty":-3.444923,"median":-1.768203,"eighty":-0.766929,"marketCap":225238952},{"date":"2025-08-08","current":-1.301335,"twenty":-3.442045,"median":-1.745417,"eighty":-0.761839,"marketCap":446809517},{"date":"2025-08-15","current":-2.007939,"twenty":-3.439167,"median":-1.743138,"eighty":-0.765537,"marketCap":456842285},{"date":"2025-08-22","current":-2.103991,"twenty":-3.427655,"median":-1.761367,"eighty":-0.766929,"marketCap":478695789},{"date":"2025-08-29","current":-2.14973,"twenty":-3.424777,"median":-1.805264,"eighty":-0.766929,"marketCap":489102219},{"date":"2025-09-05","current":-2.103991,"twenty":-3.415567,"median":-1.826307,"eighty":-0.771366,"marketCap":478695789},{"date":"2025-09-12","current":-1.994217,"twenty":-3.40866,"median":-1.836561,"eighty":-0.773109,"marketCap":453720356},{"date":"2025-09-19","current":-1.9622,"twenty":-3.406179,"median":-1.867544,"eighty":-0.787793,"marketCap":446435855},{"date":"2025-09-26","current":-1.824983,"twenty":-3.405847,"median":-1.875296,"eighty":-0.795863,"marketCap":415216564},{"date":"2025-10-03","current":-1.811262,"twenty":-3.397967,"median":-1.860219,"eighty":-0.799931,"marketCap":412094635},{"date":"2025-10-10","current":-2.071974,"twenty":-3.391392,"median":-1.873019,"eighty":-0.803629,"marketCap":471411288},{"date":"2025-10-17","current":-2.108565,"twenty":-3.371823,"median":-1.884428,"eighty":-0.807327,"marketCap":479736432},{"date":"2025-10-24","current":-2.108565,"twenty":-3.341892,"median":-1.893592,"eighty":-0.812505,"marketCap":479736432},{"date":"2025-10-31","current":-2.131434,"twenty":-3.317141,"median":-1.904969,"eighty":-0.82249,"marketCap":484939647},{"date":"2025-11-07","current":-2.158878,"twenty":-3.30563,"median":-1.911755,"eighty":-0.843135,"marketCap":491183505},{"date":"2025-11-14","current":-2.422653,"twenty":-3.301601,"median":-1.918592,"eighty":-0.848547,"marketCap":551197167},{"date":"2025-11-21","current":-2.946741,"twenty":-3.29642,"median":-1.93682,"eighty":-0.86502,"marketCap":722402348},{"date":"2025-11-28","current":-3.266113,"twenty":-3.290089,"median":-1.953052,"eighty":-0.869088,"marketCap":800697401},{"date":"2025-12-05","current":-3.534386,"twenty":-3.297571,"median":-1.962042,"eighty":-0.870197,"marketCap":866465244},{"date":"2025-12-12","current":-4.943882,"twenty":-3.336738,"median":-1.966442,"eighty":-0.879813,"marketCap":1212007408},{"date":"2025-12-19","current":-4.709675,"twenty":-3.399937,"median":-1.972322,"eighty":-0.888607,"marketCap":1154591037},{"date":"2025-12-26","current":-4.854457,"twenty":-3.410963,"median":-1.990368,"eighty":-0.898223,"marketCap":1190084794},{"date":"2026-01-02","current":-4.156097,"twenty":-3.436865,"median":-1.996504,"eighty":-0.911618,"marketCap":1018879613},{"date":"2026-01-09","current":-7.741582,"twenty":-3.449528,"median":-2.003365,"eighty":-0.920124,"marketCap":1897872066},{"date":"2026-01-16","current":-12.290084,"twenty":-3.466829,"median":-2.013154,"eighty":-0.925671,"marketCap":3012950964},{"date":"2026-01-23","current":-13.362987,"twenty":-3.516406,"median":-2.019374,"eighty":-0.930109,"marketCap":3275976472},{"date":"2026-01-30","current":-13.647739,"twenty":-3.577828,"median":-2.030809,"eighty":-0.937506,"marketCap":3345784190},{"date":"2026-02-06","current":-13.393497,"twenty":-3.626234,"median":-2.053678,"eighty":-0.942816,"marketCap":3283455871},{"date":"2026-02-13","current":-13.6274,"twenty":-3.672282,"median":-2.062826,"eighty":-0.944902,"marketCap":3340797925},{"date":"2026-02-20","current":-14.850306,"twenty":-3.690125,"median":-2.071974,"eighty":-0.965612,"marketCap":3640597141},{"date":"2026-02-24","current":-14.059612,"twenty":-3.708544,"median":-2.081121,"eighty":-0.973379,"marketCap":3446756068}],"updateTime":1772036016132},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALMS\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1191699696","title":"Alumis (ALMS.US) Soars Over 154% at Open on Positive Phase 3 Psoriasis Drug Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1191699696","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191699696?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:47","pubTimestamp":1767710838,"startTime":"0","endTime":"0","summary":"On Tuesday, Alumis Inc. (ALMS.US) skyrocketed more than 154% at the opening bell, reaching a record high of $20.60. The surge followed the company's announcement of positive top-line results from the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"1185068193","title":"Stock Track | Alumis Inc. Soars 167.51% in Pre-Market on Positive Phase 3 Psoriasis Drug Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1185068193","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185068193?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:32","pubTimestamp":1767709952,"startTime":"0","endTime":"0","summary":"Alumis Inc. (ALMS) saw its stock surge by 167.51% in pre-market trading on Tuesday following the announcement of positive Phase 3 trial results for its experimental drug, envudeucitinib, in treating...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ALMS"],"gpt_icon":0},{"id":"2601813267","title":"Alumis Shares Jump 155% to $21 After Co's Skin Disease Drug Meets Main Goal of Two Late Stage Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2601813267","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601813267?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:32","pubTimestamp":1767709942,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y7132:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2601180648","title":"BUZZ-U.S. STOCKS ON THE MOVE-Alkermes, Ball Corp, NovaBridge","url":"https://stock-news.laohu8.com/highlight/detail?id=2601180648","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601180648?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:12","pubTimestamp":1767708743,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Alkermes, Ball Corp, NovaBridgeEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ht","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL6N3Y70M6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERX","BK","ZETA","ANGO","HL","NEM","ACRS","NBP","OS","REGN","NVDU","NVDX","FERG","CDE","GL","RTO.UK","NVDY","ACN","MCHP","INTU","ALKS","AEVA","ALB","O","VST","GNPX","JXN","NVDS","AU","BALL","STT","NVDS.UK","IFF","HGT.UK","ALMS","NTRS","NVD2.UK","NVD3.UK","APGE","VRTX","AIG","GILD","NVIW.SI","CRNX","UAA"],"gpt_icon":1},{"id":"2601906518","title":"Alumis Exec Says Co Believes Envudeucitinib Is \"Very Competitive\" With Takeda's Zasocitinib - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2601906518","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601906518?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:32","pubTimestamp":1767706371,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y70CL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2601892026","title":"Alumis Shares Surge 90% as Its Skin Disease Drug Meets Main Goal in Late-Stage Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2601892026","media":"Reuters","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601892026?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:05","pubTimestamp":1767704755,"startTime":"0","endTime":"0","summary":"$Alumis(ALMS)$ said on Tuesday its experimental drug to treat a common skin disease met the main goal in two late-stage studies, offering hope for a new oral treatment option that affects millions of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL4N3Y70Q5:2","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Alumis' Skin Disease Drug Meets Main Goal in Late-Stage Trials","news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BFXG1179.USD","LU1670711040.USD","LU2242646821.SGD","LU1868836757.USD","LU0289739699.SGD","LU0321505868.SGD","BK4007","IE00BSNM7G36.USD","LU1983299246.USD","BK4585","LU1670711123.USD","LU0122379950.USD","LU0109394709.USD","IE00BJJMRZ35.SGD","LU0267386448.USD","LU1057294990.SGD","LU0306806265.USD","LU1670710661.SGD","IE00B4R5TH58.HKD","LU2089984988.USD","SG9999001440.SGD","IE00BJT1NW94.SGD","LU0321505439.SGD","LU0306807586.USD","LU1868837300.USD","LU2125154935.USD","LU1868836914.USD","LU1323610961.USD","LU1093756168.USD","LU1989771016.USD","BK4559","LU1261432733.SGD","LU1670710588.SGD","LU0114720955.EUR","IE0002141913.USD","LU1868837136.USD","LU0096364046.USD","LU1093756325.SGD","LU1868836591.USD","LU0868494617.USD","LU1061106388.HKD","LU2242652126.USD","LU1571399168.USD","LU0058720904.USD","LU1032466523.USD","LU2468319806.SGD","ALMS"],"gpt_icon":0},{"id":"1170812989","title":"Stock Track | Alumis Inc. Soars 94.46% in Pre-Market After Positive Phase 3 Psoriasis Drug Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1170812989","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170812989?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:02","pubTimestamp":1767704550,"startTime":"0","endTime":"0","summary":"Alumis Inc. (ALMS) shares surged 94.46% in pre-market trading on Tuesday following the announcement of positive Phase 3 trial results for its experimental drug, envudeucitinib, in treating...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ALMS"],"gpt_icon":0},{"id":"2601892178","title":"Alumis Shares Extend Premarket Gains, Last up 104% at $17","url":"https://stock-news.laohu8.com/highlight/detail?id=2601892178","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601892178?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:43","pubTimestamp":1767703428,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL4N3Y70S2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2601946208","title":"Alumis Shares Jump 17.2% to $9.74 Premarket After Co's Skin Disease Drug Meets Main Goal of Two Late Stage Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2601946208","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601946208?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:08","pubTimestamp":1767701314,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL4N3Y70QC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2601943798","title":"Alumis Inc - Envudeucitinib Shows Favorable Safety and Tolerability Profile Consistent With the Phase 2 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2601943798","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601943798?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:01","pubTimestamp":1767700862,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y61AE:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2601894320","title":"Alumis Inc - Phase 3 Trials Meet All Endpoints With High Statistical Significance","url":"https://stock-news.laohu8.com/highlight/detail?id=2601894320","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601894320?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:01","pubTimestamp":1767700862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y61AE:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2601894305","title":"Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2601894305","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601894305?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:01","pubTimestamp":1767700862,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y61AE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2601389437","title":"Alumis Inc - to Submit New Drug Application to FDA in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601389437","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601389437?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:01","pubTimestamp":1767700862,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y61AE:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2601322894","title":"Alumis Inc - Topline Data From Lumus Phase 2B Trial of Envudeucitinib in Sle Expected to Be Announced in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601322894","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601322894?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:01","pubTimestamp":1767700862,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y61AE:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2601872894","title":"Alumis Reports Positive Phase 3 Results for Envudeucitinib in Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2601872894","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601872894?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:00","pubTimestamp":1767700823,"startTime":"0","endTime":"0","summary":"Alumis Inc. announced positive topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials evaluating envudeucitinib, a next-generation oral TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis. Both trials met all primary and secondary endpoints, with approximately 65% of patients achieving PASI 90 and more than 40% reaching PASI 100 at Week 24. The safety and tolerability profile of envudeucitinib was consistent with previous studies, with no new safety signals observed. Alumis plans to submit a New Drug Application to the FDA in the second half of 2026. Additional results from the ONWARD1 and ONWARD2 trials will be presented at an upcoming medical meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL7HZc7r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014005.SGD","SG9999014021.USD","IE00B64PRP62.GBP","BK4007","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU0314104364.USD","LU2210150020.SGD","SG9999014013.SGD","ALMS","BK4585","BK4588","LU2210149790.SGD","NDAQ","SG9999014039.USD","BK4112"],"gpt_icon":0},{"id":"2601885555","title":"Stocks to Watch: Cyclerion, Vistra, Zeta Global, Alumis","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885555","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601885555?lang=en_us&edition=fundamental","pubTime":"2026-01-06 07:43","pubTimestamp":1767656580,"startTime":"0","endTime":"0","summary":"Cyclerion Therapeutics entered an agreement to integrate Medsteer's anesthetic delivery technology into its lead program, CYC-126, which is in development for treatment-resistant depression. The collaboration aims to accelerate the development of CYC-126 and reduce technical and execution risks, the biopharmaceutical company said. The stock jumped 49% to $2.06 in after-hours trading.Vistra plans to acquire Cogentrix Energy from Quantum Capital Group in a deal valued at about $4 billion, including cash, equity and debt. The electricity and power-generation company said the acquisition would include 10 natural gas generation facilities totaling about 5,500 megawatts of capacity, helping it meet growing customer demand and diversify its geographic footprint. Shares rose 4.8% to $170.76 in late trading.Zeta Global disclosed plans to use OpenAI's models to support its artificial intelligence agent for enterprise marketing. Zeta will also have the opportunity for early access to new OpenAI m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","ZETA","ALMS","IE00BFMHRM44.USD","BK4613","BK4539","BK4007"],"gpt_icon":0},{"id":"2601853109","title":"Alumis Shares Rise on Plans to Share Trial Data for Plaque Psoriasis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2601853109","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601853109?lang=en_us&edition=fundamental","pubTime":"2026-01-06 07:12","pubTimestamp":1767654720,"startTime":"0","endTime":"0","summary":"Shares of Alumis gained on plans to share topline data from a Phase 3 trial evaluating envudeucitinib to treat moderate-to-severe plaque psoriasis.The stock rose 8.9% to $9.05 in after-hours trading on Monday. Through market close, shares have more than doubled in the past three months.The biopharmaceutical company said it will report the data on Tuesday and host a conference call to discuss the results the same day.The company had said in November it expected to share the topline results early in the first quarter. The data, as well as expected results from a trial evaluating the therapy in systemic lupus erythematosus, could validate envu's differentiated profile and unlock further opportunities across immune-mediated diseases, Alumis said at the time.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2601858882","title":"Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2601858882","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601858882?lang=en_us&edition=fundamental","pubTime":"2026-01-06 06:00","pubTimestamp":1767650400,"startTime":"0","endTime":"0","summary":"Teri Dahlman. Red House Communications. teri@redhousecomms.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/05/3213244/0/en/Alumis-to-Host-Conference-Call-and-Webcast-to-Report-Phase-3-ONWARD-Topline-Data-for-Envudeucitinib-in-Moderate-to-Severe-Plaque-Psoriasis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4585","BK4588","HST","BK4181","BK4007","BK4218"],"gpt_icon":0},{"id":"2600093014","title":"BRIEF-Alumis Inc - Co & Its Unit Issues Notice Of Material Breach  & Notification Of Claim For Indemnification To Climb Bio - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2600093014","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600093014?lang=en_us&edition=fundamental","pubTime":"2026-01-03 06:09","pubTimestamp":1767391751,"startTime":"0","endTime":"0","summary":"BRIEF-Alumis Inc - Co & Its Unit Issues Notice Of Material Breach  & Notification Of Claim For Indemnification To Climb Bio - SEC FilingJan 2  - Alumis Inc ALMS.O:ALUMIS INC - CO & ITS UNIT ISSUES NOTICE OF MATERIAL BREACH  & NOTIFICATION OF CLAIM FOR INDEMNIFICATION TO CLIMB BIO - SEC FILINGALUMIS INC - CLIMB BIO REFUSES TO PAY $3,000,000 DEVELOPMENT MILESTONE PAYMENT DUE JAN 1, 2026 - SEC FILINGSource text: [ID:n0001104659-26-000197]Further company coverage: ALMS.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nFWN3Y30CH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2600757098","title":"Alumis Inc - Co & Its Unit Issues Notice of Material Breach  & Notification of Claim for Indemnification to Climb Bio - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2600757098","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600757098?lang=en_us&edition=fundamental","pubTime":"2026-01-03 05:08","pubTimestamp":1767388106,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nFWN3Y30CH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":93,"code":"91000000","status":"200"}]}}